Sarepta Therapeutics
SRPT
375 hedge funds and large institutions have $9.25B invested in Sarepta Therapeutics in 2022 Q3 according to their latest regulatory filings, with 81 funds opening new positions, 122 increasing their positions, 114 reducing their positions, and 36 closing their positions.
125% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 36
69% more capital invested
Capital invested by funds: $5.49B → $9.25B (+$3.76B)
68% more call options, than puts
Call options by funds: $269M | Put options by funds: $160M
13% more funds holding
Funds holding: 331 → 375 (+44)
12.88% more ownership
Funds ownership: 83.85% → 96.73% (+13%)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
7% more repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 114
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$577M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$95.6M |
| 3 |
O
OrbiMed
New York
|
+$90.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$89M |
| 5 |
Two Sigma Investments
New York
|
+$76.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$124M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$47.5M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$43.4M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$38.7M |
| 5 |
State Street
Boston,
Massachusetts
|
-$38.5M |
SRPT Hedge Fund Activity: Q3 2022 in Review
375 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2022, worth a combined $9.25B — up 69% from $5.49B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new SRPT positions and 36 closed out — a net gain of 45 holders — while 122 added to existing stakes and 114 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $577M. The largest seller was Sands Capital Management, cutting an estimated $124M.
- 375 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2022, up from 331 in Q2 2022.
- Funds reported $9.25B of Sarepta Therapeutics stock for Q3 2022, up 69% quarter-over-quarter.
- 81 funds opened new Sarepta Therapeutics positions in Q3 2022 and 36 closed out, a net change of +45 holders.
- The largest Sarepta Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $577M added.
- The largest Sarepta Therapeutics seller in Q3 2022 was Sands Capital Management, an estimated $124M sold.
Based on aggregated 13F filings for Q3 2022.